Janssen Wins EU Fast-Track Status For CAR-T Therapy Cilta-Cel
Filing Of Potential Multiple Myeloma Treatment Planned For H1
Three requests for the accelerated assessment of planned EU marketing applications were considered by the European Medicines Agency last month.
